ETC-1002 and Statin Fixed-Dose Combination for LDL-C Reduction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing treatments for cardiovascular disease, particularly those involving statins, often fail to adequately lower LDL-C levels in patients and are associated with negative side effects such as muscle-related symptoms and systemic toxicity.
Innovation Solution
The use of a fixed-dose combination of ETC-1002 (bempedoic acid) and statins, which inhibits ATP citrate lyase to reduce cholesterol synthesis and increase LDL receptor expression, thereby achieving further reductions in total cholesterol and LDL-C levels.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If statins are used to lower cholesterol levels, then LDL-C reduction is achieved, but muscle-related side effects and systemic toxicity occur
Solution Approach 1:
The patent segments the cholesterol-lowering function into two separate agents: ETC-1002 (bempedoic acid) that acts on ATP citrate lyase in the liver to reduce cholesterol synthesis, and statins that act on HMG-CoA reductase. By dividing the therapeutic approach, the patent achieves enhanced LDL-C reduction while allowing ETC-1002 to counteract the muscle-related side effects of statins, as ETC-1002 does not cross into muscle tissue to the same extent.
Solution Approach 2:
ETC-1002 serves as an intermediary agent that modifies the metabolic pathway upstream of HMG-CoA reductase by inhibiting ATP citrate lyase. This intermediary action reduces the substrate availability for cholesterol synthesis, thereby enhancing the effectiveness of statins while reducing the required statin dose and mitigating their toxic side effects.
2Quantity of substance
If higher doses of statins are administered to achieve greater LDL-C reduction, then cholesterol levels decrease further, but side effects increase
Solution Approach 1:
The patent employs partial action by using ETC-1002 to inhibit ATP citrate lyase, which is upstream in the cholesterol synthesis pathway. This partial inhibition at an earlier stage reduces the burden on HMG-CoA reductase, allowing statins to work at lower doses while achieving the same or greater LDL-C reduction, thereby avoiding the excessive dosing that leads to side effects.
Solution Approach 2:
The patent combines ETC-1002 and statins into a fixed-dose combination therapy that merges two complementary mechanisms of action. This combination allows for synergistic LDL-C reduction where the lower dose of statin required due to ETC-1002's upstream inhibition results in fewer side effects while maintaining efficacy.
3Quantity of substance
If traditional cholesterol therapies are used, then some LDL-C reduction is achieved, but residual cardiovascular risk remains in high-cholesterol patients
Solution Approach 1:
The patent establishes continuity of useful action by targeting two sequential steps in the cholesterol synthesis pathway: ETC-1002 continuously inhibits ATP citrate lyase upstream, while statins continuously inhibit HMG-CoA reductase downstream. This continuous dual-action approach ensures sustained and more profound LDL-C reduction compared to single-agent therapy, thereby reducing residual cardiovascular risk more effectively.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This combination therapy demonstrates increased efficacy and safety in lowering LDL-C levels compared to monotherapy with either ETC-1002 or statins, particularly in patients with persistent elevated LDL-C despite stable statin therapy.
Implementation Method 1
ETC-1002 lowers low-density lipoprotein cholesterol (LDL-C) by direct inhibition of hepatic adenosine triphosphate citrate lyase, leading to reduced de novo cholesterol synthesis
Implementation Method 2
ETC-1002 lowers low-density lipoprotein cholesterol (LDL-C) by direct inhibition of hepatic adenosine triphosphate citrate lyase, leading to reduced de novo cholesterol synthesis and increased LDL receptor expression
Implementation Method 3
The general class of 'statins' are compounds which lower cholesterol levels in the body by inhibiting the enzyme 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase and concomitantly, the pathway for synthesizing cholesterol in the liver
Data Source
AI summary
Disclosed herein are compositions comprising fixed doses of ETC-1002 and one or more statins. Also disclosed herein are methods for using fixed doses of ETC-1002 and one or more statins. Uses include methods of treating cardiovascular disease or reducing the risk of cardiovascular disease in a subject. Uses also include methods of treating hypercholesterolemia in a subject.